Cargando…
A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231335/ https://www.ncbi.nlm.nih.gov/pubmed/32326233 http://dx.doi.org/10.3390/mi11040436 |
_version_ | 1783535167702302720 |
---|---|
author | Kojima, Hideto Raut, Bibek Chen, Li-Jiun Nagai, Nobuhiro Abe, Toshiaki Kaji, Hirokazu |
author_facet | Kojima, Hideto Raut, Bibek Chen, Li-Jiun Nagai, Nobuhiro Abe, Toshiaki Kaji, Hirokazu |
author_sort | Kojima, Hideto |
collection | PubMed |
description | Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epithelial (ARPE-19) cells (cultured on collagen coated polystyrene (PS) sheets) enclosed inside a 3D printed semi-porous capsule. The capsule was 3D printed with two photo curable polymers: triethylene glycol dimethacrylate (TEGDM) and polyethylene glycol dimethylacrylate (PEGDM). The capsule’s semi-porous membrane (PEGDM) could serve three functions: protecting the cells from body’s immune system by limiting diffusion (5.97 ± 0.11%) of large molecules like immunoglobin G (IgG)(150 kDa); helping the cells to survive inside the capsule by allowing diffusion (43.20 ± 2.16%) of small molecules (40 kDa) like oxygen and necessary nutrients; and helping in the treatment of RDD by allowing diffusion of cell-secreted BDNF to the outside environment. In vitro results showed a continuous BDNF secretion from the device for at least 16 days, demonstrating future potential of the cell-encapsulation device for the treatment of RDD in a minimally invasive and self-sustainable way through a periocular transplant. |
format | Online Article Text |
id | pubmed-7231335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72313352020-05-22 A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases Kojima, Hideto Raut, Bibek Chen, Li-Jiun Nagai, Nobuhiro Abe, Toshiaki Kaji, Hirokazu Micromachines (Basel) Article Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epithelial (ARPE-19) cells (cultured on collagen coated polystyrene (PS) sheets) enclosed inside a 3D printed semi-porous capsule. The capsule was 3D printed with two photo curable polymers: triethylene glycol dimethacrylate (TEGDM) and polyethylene glycol dimethylacrylate (PEGDM). The capsule’s semi-porous membrane (PEGDM) could serve three functions: protecting the cells from body’s immune system by limiting diffusion (5.97 ± 0.11%) of large molecules like immunoglobin G (IgG)(150 kDa); helping the cells to survive inside the capsule by allowing diffusion (43.20 ± 2.16%) of small molecules (40 kDa) like oxygen and necessary nutrients; and helping in the treatment of RDD by allowing diffusion of cell-secreted BDNF to the outside environment. In vitro results showed a continuous BDNF secretion from the device for at least 16 days, demonstrating future potential of the cell-encapsulation device for the treatment of RDD in a minimally invasive and self-sustainable way through a periocular transplant. MDPI 2020-04-21 /pmc/articles/PMC7231335/ /pubmed/32326233 http://dx.doi.org/10.3390/mi11040436 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kojima, Hideto Raut, Bibek Chen, Li-Jiun Nagai, Nobuhiro Abe, Toshiaki Kaji, Hirokazu A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases |
title | A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases |
title_full | A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases |
title_fullStr | A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases |
title_full_unstemmed | A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases |
title_short | A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases |
title_sort | 3d printed self-sustainable cell-encapsulation drug delivery device for periocular transplant-based treatment of retinal degenerative diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231335/ https://www.ncbi.nlm.nih.gov/pubmed/32326233 http://dx.doi.org/10.3390/mi11040436 |
work_keys_str_mv | AT kojimahideto a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT rautbibek a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT chenlijiun a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT nagainobuhiro a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT abetoshiaki a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT kajihirokazu a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT kojimahideto 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT rautbibek 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT chenlijiun 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT nagainobuhiro 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT abetoshiaki 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases AT kajihirokazu 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases |